Discover
CING
Cingulate Inc.
5.89
2 x 4.31
2 x 6.93
bid
ask
+
0.42
7.68%
2 @ 05:43 AM
6.00 +0.11 (1.87%)
| Ytd | 35.71% | |
| 1y | 42.27% |
5.31
day range
6.04
3.16
52 week range
11.89
| Open | 5.40 | Prev Close | 5.47 | Low | 5.31 | High | 6.04 | Mkt Cap | 79.33M |
| Vol | 393.89K | Avg Vol | 559.43K | EPS | -4.33 | P/E | N/A | Forward P/E | -0.65 |
| Beta | -0.91 | Short Ratio | 0.69 | Inst. Own | 1.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 4.88 | 200-d Avg | 5.00 | 1yr Est | 48.33 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -2.22 | -1.83 | 0.39 | 17.57% |
| 2024-08-13 | 2024-06 | 0 | N/A | N/A | N/A |
| 2024-08-13 | 2024-06 | 0 | -5.47 | N/A | N/A |
| 2024-05-08 | 2024-03 | -26.41 | -7.2 | 19.21 | 72.74% |
| 2024-05-08 | 2024-03 | -26.41 | N/A | N/A | N/A |
| 2024-04-05 | 2023-12 | -2.6 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-20 | Maxim Group | Upgrade | Hold | Buy |
| 2024-01-05 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-12-22 | Laidlaw & Co. | Downgrade | Buy | Hold |
| 2023-12-19 | Maxim Group | Downgrade | Buy | Hold |
| 2023-12-18 | Maxim Group | Downgrade | Buy | Hold |
Profile
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-09-14 | CALLAHAN JENNIFER L. | Officer | 45.51K | Purchase |
| 2024-08-14 | MYERS LAURIE | Chief Operating Officer | 0.00 | Sale |
| 2024-04-10 | WERTH PETER J. | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Jane Street Group, LLC | 21.03K | 100.11K | 0.65% |
| 2024-09-29 | UBS Group AG | 13.75K | 65.44K | 0.43% |
| 2024-09-29 | Commonwealth Equity Services, LLC | 11.28K | 53.67K | 0.35% |
| 2024-09-29 | Bank of America Corporation | 1.88K | 8.94K | 0.06% |
| 2024-09-29 | Tower Research Capital LLC (TRC) | 1.57K | 7.48K | 0.05% |
| 2024-09-29 | FMR, LLC | 352.00 | 1.68K | 0.01% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 4.54K | 21.62K | 0.14% |
| 2024-10-30 | Fidelity Total Market Index Fund | 1.76K | 8.35K | 0.05% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 1.30K | 6.20K | 0.04% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 530.00 | 2.52K | 0.02% |
Split
| Split | Date |
|---|---|
| 1 : 12 | 2024-08-09 |
| 1 : 20 | 2023-11-30 |